Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 2/2023

24-01-2023 | Computed Tomography | Case Report

Histology and cytokine levels in hepatic injury accompanying a case of non-severe COVID-19

Authors: Hidetaka Matsuda, Takuto Nosaka, Katsushi Hiramatsu, Kazuto Takahashi, Tatsushi Naito, Kazuya Ofuji, Masahiro Ohtani, Yoshiaki Imamura, Hiromichi Iwasaki, Yasunari Nakamoto

Published in: Clinical Journal of Gastroenterology | Issue 2/2023

Login to get access

Abstract

The pathogenesis of liver dysfunction that complicates coronavirus disease 2019 (COVID-19) remains unclear, especially in mild to moderate severity cases. In this case, a novel coronavirus infection was detected by polymerase chain reaction (PCR) in a 76-year-old woman hospitalized after presenting with fever. No other abnormal physical findings were observed, and oxygen administration was not required. Chest computed tomography (CT) showed a ground-glass-like and an infiltrative shadow in the right lung, and moderate COVID-19 was diagnosed. Initially, the fever resolved, and PCR turned negative; however, the fever reappeared on hospitalization day 14, and CT showed pneumonia exacerbation accompanied by new onset of fatty liver. Biochemical testing revealed marked liver dysfunction, accompanied by elevated serum interleukin (IL)-6, IL-10, and tumor necrosis factor-α levels. Physical findings and all laboratory parameters improved after conservative treatment, and she was discharged on day 22. A liver biopsy performed 44 days post-discharge showed T-cell-dominant inflammatory cell infiltration, mainly in the portal region. Some hepatocytes showed fatty degeneration.
We report a case of moderate COVID-19 in which histological hepatitis persisted after a substantial period had passed since the initial infection had cleared and associated transaminase elevations had resolved, with a comparison of serum cytokine dynamics.
Literature
4.
go back to reference Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: the current evidence. Unit Europ Gastroenterol J. 2020;8:509–19.CrossRef Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: the current evidence. Unit Europ Gastroenterol J. 2020;8:509–19.CrossRef
6.
go back to reference Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.CrossRefPubMedPubMedCentral Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.CrossRefPubMedPubMedCentral
7.
go back to reference Wang Y, Liu S, Liu H, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020;73:807–16.CrossRefPubMedPubMedCentral Wang Y, Liu S, Liu H, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020;73:807–16.CrossRefPubMedPubMedCentral
8.
go back to reference Wang Q, Zhao H, Liu LG, et al. Pattern of liver injury in adult patients with COVID-19: a retrospective analysis of 105 patients. Mil Med Res. 2020;7:28.PubMedPubMedCentral Wang Q, Zhao H, Liu LG, et al. Pattern of liver injury in adult patients with COVID-19: a retrospective analysis of 105 patients. Mil Med Res. 2020;7:28.PubMedPubMedCentral
9.
go back to reference Uchida Y, Uemura H, Yamaba S, et al. Significance of liver dysfunction associated with decreased hepatic CT attenuation values in Japanese patients with severe COVID-19. J Gastroenterol. 2020;55:1098–106.CrossRefPubMedPubMedCentral Uchida Y, Uemura H, Yamaba S, et al. Significance of liver dysfunction associated with decreased hepatic CT attenuation values in Japanese patients with severe COVID-19. J Gastroenterol. 2020;55:1098–106.CrossRefPubMedPubMedCentral
10.
go back to reference Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:667–78.CrossRefPubMedPubMedCentral Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:667–78.CrossRefPubMedPubMedCentral
11.
go back to reference Fix OK, Hameed B, Fontana RJ, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology. 2020;72:287–304.CrossRefPubMed Fix OK, Hameed B, Fontana RJ, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology. 2020;72:287–304.CrossRefPubMed
13.
14.
go back to reference Sonzogni A, Previtali G, Seghezzi M, et al. Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations. Liver Int. 2020;40:2110–6.CrossRefPubMedPubMedCentral Sonzogni A, Previtali G, Seghezzi M, et al. Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations. Liver Int. 2020;40:2110–6.CrossRefPubMedPubMedCentral
15.
go back to reference Tahtabasi M, Hosbul T, Karaman E, et al. Frequency of hepatic steatosis and its association with the pneumonia severity score on chest computed tomography in adult COVID-19 patients. World J Crit Care Med. 2021;10:47–57.CrossRefPubMedPubMedCentral Tahtabasi M, Hosbul T, Karaman E, et al. Frequency of hepatic steatosis and its association with the pneumonia severity score on chest computed tomography in adult COVID-19 patients. World J Crit Care Med. 2021;10:47–57.CrossRefPubMedPubMedCentral
16.
go back to reference Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ EBM. 2021;26:107–8.CrossRef Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ EBM. 2021;26:107–8.CrossRef
17.
go back to reference Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Trans. 2020;39:405–7.CrossRef Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Trans. 2020;39:405–7.CrossRef
18.
go back to reference Cevik M, Kuppalli K, Kindrachuk J, et al. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371:m3862.CrossRefPubMed Cevik M, Kuppalli K, Kindrachuk J, et al. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371:m3862.CrossRefPubMed
19.
go back to reference Torre D, Zeroli C, Giola M, et al. Serum levels of interleukin-1 alpha, interleukin-1 beta, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis. Clin Infect Dis. 1994;18:194–8.CrossRefPubMed Torre D, Zeroli C, Giola M, et al. Serum levels of interleukin-1 alpha, interleukin-1 beta, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis. Clin Infect Dis. 1994;18:194–8.CrossRefPubMed
20.
go back to reference Arya RP, Arankalle VA. Phenotypic analysis of monocytes and CD4(+) T cells in hepatitis E patients with or without pregnancy. Hum Immunol. 2019;80(10):855–62.CrossRefPubMed Arya RP, Arankalle VA. Phenotypic analysis of monocytes and CD4(+) T cells in hepatitis E patients with or without pregnancy. Hum Immunol. 2019;80(10):855–62.CrossRefPubMed
21.
go back to reference Ribeiro CRA, Beghini DG, Lemos AS, et al. Cytokines profile in patients with acute and chronic hepatitis B infection. Microbiol Immunol. 2022;66:31–9.CrossRefPubMed Ribeiro CRA, Beghini DG, Lemos AS, et al. Cytokines profile in patients with acute and chronic hepatitis B infection. Microbiol Immunol. 2022;66:31–9.CrossRefPubMed
22.
go back to reference Sato S, Kawashima H, Oshiro H, et al. Virological and immunological characteristics of a 19 year-old Japanese female with fatal outcome with Epstein-Barr virus-associated hemophagocytic syndrome. J Clin Virol. 2004;31:235–8.CrossRefPubMed Sato S, Kawashima H, Oshiro H, et al. Virological and immunological characteristics of a 19 year-old Japanese female with fatal outcome with Epstein-Barr virus-associated hemophagocytic syndrome. J Clin Virol. 2004;31:235–8.CrossRefPubMed
23.
go back to reference Tetsuka S, Suzuki T, Ogawa T, et al. Encephalopathy associated with severe cytomegalovirus infection in an immunocompetent young woman. Case Rep Infect Dis. 2021;2021:5589739.PubMedPubMedCentral Tetsuka S, Suzuki T, Ogawa T, et al. Encephalopathy associated with severe cytomegalovirus infection in an immunocompetent young woman. Case Rep Infect Dis. 2021;2021:5589739.PubMedPubMedCentral
24.
go back to reference Laing AG, Lorenc A, Molino Del Barrio Del I, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020;26:1623–35.CrossRefPubMed Laing AG, Lorenc A, Molino Del Barrio Del I, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020;26:1623–35.CrossRefPubMed
25.
27.
go back to reference Grim SA, Romanelli F, Jennings PR, et al. Late-onset drug fever associated with minocycline: case report and review of the literature. Pharmacotherapy. 2003;23:1659–62.CrossRefPubMed Grim SA, Romanelli F, Jennings PR, et al. Late-onset drug fever associated with minocycline: case report and review of the literature. Pharmacotherapy. 2003;23:1659–62.CrossRefPubMed
29.
go back to reference Murai Y, Kawasuji H, Takegoshi Y, et al. A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test. Int J Infect Dis. 2021;106:33–5.CrossRefPubMedPubMedCentral Murai Y, Kawasuji H, Takegoshi Y, et al. A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test. Int J Infect Dis. 2021;106:33–5.CrossRefPubMedPubMedCentral
31.
go back to reference Tsutsumi T, Saito M, Nagai H, et al. Association of coagulopathy with liver dysfunction in patients with COVID-19. Hepatol Res. 2021;51:227–32.CrossRefPubMed Tsutsumi T, Saito M, Nagai H, et al. Association of coagulopathy with liver dysfunction in patients with COVID-19. Hepatol Res. 2021;51:227–32.CrossRefPubMed
32.
go back to reference Kondo R, Kawaguchi N, McConnell MJ, et al. Pathological characteristics of liver sinusoidal thrombosis in COVID-19 patients: a series of 43 cases. Hepatol Res. 2021;51:1000–6.CrossRefPubMedPubMedCentral Kondo R, Kawaguchi N, McConnell MJ, et al. Pathological characteristics of liver sinusoidal thrombosis in COVID-19 patients: a series of 43 cases. Hepatol Res. 2021;51:1000–6.CrossRefPubMedPubMedCentral
33.
go back to reference Nishikawa M, Kanno H, Zhou Y, et al. Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19. Nat Commun. 2021;12:7135.CrossRefPubMedPubMedCentral Nishikawa M, Kanno H, Zhou Y, et al. Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19. Nat Commun. 2021;12:7135.CrossRefPubMedPubMedCentral
Metadata
Title
Histology and cytokine levels in hepatic injury accompanying a case of non-severe COVID-19
Authors
Hidetaka Matsuda
Takuto Nosaka
Katsushi Hiramatsu
Kazuto Takahashi
Tatsushi Naito
Kazuya Ofuji
Masahiro Ohtani
Yoshiaki Imamura
Hiromichi Iwasaki
Yasunari Nakamoto
Publication date
24-01-2023
Publisher
Springer Nature Singapore
Published in
Clinical Journal of Gastroenterology / Issue 2/2023
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-023-01755-4

Other articles of this Issue 2/2023

Clinical Journal of Gastroenterology 2/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine